The Primary Progressive Aphasia (PPA) Program provides individual and group treatment for clients who who are experiencing a decline in communication abilities consistent with PPA. This program ...
Kite, a Gilead Company , today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous ...
Axon Neuroscience’s active tau immunotherapy, AADvac1, has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Phase 2 Alzheimer’s disease clinical trial, while ...
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...
By Mariam Sunny Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy slowed disease ...
In the U.S., a stroke happens roughly every 40 seconds. That means, in the time it takes to read a five-minute news article, ...
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, ...
The primary focus of this lab is to work with people with aphasia – a language impairment that sometimes follows stroke – to better understand language processes and ways to improve aphasia treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results